Enzymatic production of optically pure (2'R-cis)-2'-deoxy-3'-thiacytidine (3TC, lamivudine): a potent anti-HIV agent. 1993

M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
Department of Natural Products Discovery, Glaxo Group Research Ltd, Greenford, Middlesex, England.

Although equipotent in terms of antiviral activity, the two enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) differ markedly in their cytotoxicity. (2'R-cis)-2'-deoxy-3'-thiacytidine (3TC) is substantially less toxic than its optical antipode, and is undergoing development for the therapy of HIV infection. Cytidine deaminase from Escherichia coli is shown here to deaminate 2'-deoxy-3'-thiacytidine enantioselectively to leave 3TC essentially optically pure. This reaction has been used to develop a process for production of 3TC in multikilogram amounts. The production of cytidine deaminase was enhanced by strain improvement, fermentation development, and finally by cloning and overexpression of the gene. The enzyme was immobilized on Eupergit-C, which allowed it to be reused many times. The biotransformation conditions were optimized so that the best use could be made of the catalyst. A robust scaleable product isolation process was developed to yield the crystalline product. Overall, yields through the resolution process of 76% were obtained. All aspects of this process are capable of substantial further scaleup with only minor modifications.

UI MeSH Term Description Entries
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D004800 Enzymes, Immobilized Enzymes which are immobilized on or in a variety of water-soluble or water-insoluble matrices with little or no loss of their catalytic activity. Since they can be reused continuously, immobilized enzymes have found wide application in the industrial, medical and research fields. Immobilized Enzymes,Enzyme, Immobilized,Immobilized Enzyme
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005798 Genes, Bacterial The functional hereditary units of BACTERIA. Bacterial Gene,Bacterial Genes,Gene, Bacterial
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001709 Biotechnology Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction. Biotechnologies
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC

Related Publications

M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
June 1993, Clinical and experimental immunology,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
April 1996, Antiviral therapy,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
August 1996, Biochemical and biophysical research communications,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
September 1995, Biochemical pharmacology,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
February 1994, Journal of pharmaceutical and biomedical analysis,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
December 1995, Pharmaceutical research,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
May 1992, Biochemical pharmacology,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
February 1993, Analytical biochemistry,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
September 2001, Journal of chromatography. B, Biomedical sciences and applications,
M Mahmoudian, and B S Baines, and C S Drake, and R S Hale, and P Jones, and J E Piercey, and D S Montgomery, and I J Purvis, and R Storer, and M J Dawson
June 1995, The Journal of infectious diseases,
Copied contents to your clipboard!